MDGL Oct 2024 290.000 put
| Previous close | 62.30 |
| Open | 62.50 |
| Bid | 85.90 |
| Ask | 92.70 |
| Strike | 290.00 |
| Expiry date | 2024-10-18 |
| Day's range | 62.30 - 62.30 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
GlobeNewswireMadrigal Pharmaceuticals to Present Multiple Rezdiffra™ (resmetirom) and Health Economics Outcomes Research Abstracts in NASH/MASH at the EASL Congress
CONSHOHOCKEN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced ten data presentations at the upcoming European Association for the Study of the Liver (EASL) Congress, taking place from June 5-8, 2024 in Milan, Italy. “The data we will be presenting at EASL further support Rezdiffra as the foundational therapy in NASH and Madrigal as the
GuruFocus.comInsider Sale at Madrigal Pharmaceuticals Inc (MDGL): Senior VP, Chief Pharmaceutical ...
On May 21, 2024, Robert Waltermire, Senior Vice President and Chief Pharmaceutical Development Officer at Madrigal Pharmaceuticals Inc (NASDAQ:MDGL), sold 1,036 shares of the company.
Simply Wall St.3 High Insider Ownership US Stocks With Up To 55% Revenue Growth
Amidst a robust week for U.S. stocks, fueled by significant advancements in AI and cloud computing from major technology firms, the market landscape appears increasingly conducive to exploring growth opportunities. In this context, companies with high insider ownership can be particularly compelling, as they often signal strong confidence from those who know the business best.
